"Thromboxane A2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS).
Below are MeSH descriptors whose meaning is more general than "Thromboxane A2".
Below are MeSH descriptors whose meaning is more specific than "Thromboxane A2".
This graph shows the total number of publications written about "Thromboxane A2" by people in this website by year, and whether "Thromboxane A2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Thromboxane A2" by people in Profiles.
Blockade of eosinophil migration by 5-lipoxygenase and cyclooxygenase inhibition in explanted guinea pig trachealis. Am J Physiol. 1995 Mar; 268(3 Pt 1):L446-54.
Thromboxane mimetics enhance adrenergic neurotransmission in the rabbit-isolated portal vein. J Cardiovasc Pharmacol. 1989 Sep; 14(3):469-74.
Leukotriene antagonists attenuate thromboxane-inducible pulmonary hypertension. Pediatr Res. 1989 Aug; 26(2):83-7.
The short-term blood biocompatibility of poly(hydroxyethyl methacrylate-co-methyl methacrylate) in an in vitro flow system measured by digital videomicroscopy. J Biomater Sci Polym Ed. 1989; 1(2):123-46.
Eicosanoid balance at early stages of experimental atherosclerosis. Its relationship with plasma fibrinolytic activity and platelet aggregation. Agents Actions Suppl. 1986; 20:225-36.
Dihomo-gamma-linolenic acid in patients with atherosclerosis: effects on platelet aggregation, plasma lipids and low-density lipoprotein-induced inhibition of prostacyclin generation. Thromb Haemost. 1984 Apr 30; 51(2):186-8.
Modification of focal cerebral ischemia by prostacyclin and indomethacin. J Neurosurg. 1983 May; 58(5):714-9.
Treatment of acute focal cerebral ischemia with prostacyclin. Stroke. 1983 Mar-Apr; 14(2):203-9.
Increased platelet activity after termination of prostacyclin infusion into man. Prostaglandins. 1981 May; 21(5):827-32.
Prostacyclin and thromboxane A2 biosynthesis capacities of heart, arteries and platelets at various stages of experimental atherosclerosis in rabbits. Atherosclerosis. 1978 Dec; 31(4):385-94.